Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ.

Br J Pharmacol. 2008 May;154(1):226-33. doi: 10.1038/bjp.2008.78. Epub 2008 Mar 10.

2.

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC.

J Neurochem. 2002 Aug;82(3):615-24.

3.

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.

J Neural Transm (Vienna). 2001;108(8-9):985-1009.

PMID:
11716151
5.
6.
7.

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR.

Eur J Neurosci. 2009 Mar;29(5):954-63. doi: 10.1111/j.1460-9568.2009.06657.x. Epub 2009 Feb 24.

PMID:
19245367
8.

Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.

Grünblatt E, Mandel S, Maor G, Youdim MB.

J Neurochem. 2001 Apr;77(1):146-56.

9.

Selegiline can mediate neuronal rescue rather than neuronal protection.

Tatton WG.

Mov Disord. 1993;8 Suppl 1:S20-30. Review.

PMID:
8302304
10.

A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.

Quinn LP, Perren MJ, Brackenborough KT, Woodhams PL, Vidgeon-Hart M, Chapman H, Pangalos MN, Upton N, Virley DJ.

J Neurosci Methods. 2007 Aug 15;164(1):43-9. Epub 2007 Apr 6. Erratum in: J Neurosci Methods. 2007 Sep 30;165(2):321.

PMID:
17498809
11.

Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

Lee EY, Lee JE, Park JH, Shin IC, Koh HC.

Toxicol Lett. 2012 Sep 18;213(3):332-44. doi: 10.1016/j.toxlet.2012.07.016. Epub 2012 Jul 27.

PMID:
22842585
12.
13.

Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

Kreisler A, Gelé P, Wiart JF, Lhermitte M, Destée A, Bordet R.

Brain Res. 2007 Mar 2;1135(1):77-84. Epub 2007 Jan 2.

PMID:
17196944
14.

Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P.

Exp Neurol. 2012 Jun;235(2):528-38. doi: 10.1016/j.expneurol.2012.02.017. Epub 2012 Mar 7.

15.

Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.

Finnegan KT, Irwin I, Delanney LE, Langston JW.

J Pharmacol Exp Ther. 1995 May;273(2):716-20.

PMID:
7752075
16.
17.

Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.

Fuller RW, Hemrick-Luecke SK, Kindt MV, Heikkila RE.

Life Sci. 1988;42(3):263-71.

PMID:
3121972
18.

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74. Epub 2001 Nov 27.

19.

L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.

Thiffault C, Lamarre-Théroux L, Quirion R, Poirier J.

Brain Res Mol Brain Res. 1997 Mar;44(2):238-44.

PMID:
9073165
20.
Items per page

Supplemental Content

Write to the Help Desk